Timothy Barabe Biography and Net Worth

Director of Selecta Biosciences

Timothy C. Barabe serves as Independent Director of the Company. Mr. Barabe retired in 2013 as Executive Vice President and Chief Financial Officer of Affymetrix, Inc. Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. Mr. Barabe served as Chief Financial Officer of Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, from 2004 to 2006. He was with Novartis AG from 1982 through August 2004, where he served in a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe received his Bachelor of Business Administration degree in Finance from the University of Massachusetts (Amherst) and his Master of Business Administration from the University of Chicago.

What is Timothy C. Barabe's net worth?: The estimated net worth of Timothy C. Barabe is at least $0.00 as of May 9th, 2022. Mr. Barabe owns 250,013 shares of Selecta Biosciences stock worth more than $0 as of April 19th. This net worth approximation does not reflect any other assets that Mr. Barabe may own. Learn More about Timothy C. Barabe's net worth.
How do I contact Timothy C. Barabe?: The corporate mailing address for Mr. Barabe and other Selecta Biosciences executives is 65 Grove Street, Watertown MA, 02472. Selecta Biosciences can also be reached via phone at (617) 923-1400 and via email at [email protected]. Learn More on Timothy C. Barabe's contact information.
Has Timothy C. Barabe been buying or selling shares of Selecta Biosciences?: Timothy C. Barabe has not been actively trading shares of Selecta Biosciences in the last ninety days. Learn More on Timothy C. Barabe's trading history.
Who are Selecta Biosciences' active insiders?: Selecta Biosciences' insider roster includes Timothy Barabe (Director), Carsten Brunn (CEO), Nishan de Silva (Director), Timothy Springer (Director), Kevin Tan (CFO), and Peter Traber (Insider). Learn More on Selecta Biosciences' active insiders.
Are insiders buying or selling shares of Selecta Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 3,637 shares worth more than $3,855.22. The most recent insider tranaction occured on September, 25th when CEO Carsten Brunn sold 2,932 shares worth more than $3,107.92. Insiders at Selecta Biosciences own 31.2% of the company. Learn More about insider trades at Selecta Biosciences.
Information on this page was last updated on 9/25/2023.

Timothy C. Barabe Insider Trading History at Selecta Biosciences

Timothy C. Barabe Buying and Selling Activity at Selecta Biosciences

Selecta Biosciences Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $1.06

$0.88

$1.26

2 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Now Open: Crypto emergency update

From InvestorPlace | Ad

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.